Paragon Biosciences is an investor and incubator that is committed to helping patients who suffer from diseases that have little to no treatment options. The company was founded by CEO Jeff Aronin on the philosophy that innovative medical treatments should be made available to patients in need as soon as possible. Its companies are developing products that treat central nervous system disorders, rare genetic dermatologic conditions, and immune system diseases.
The process which Paragon Biosciences uses to develop products is simple and effective. First, the company identifies diseases where the patient need is at its highest but treatment availability is scarce. Paragon then creates dynamic companies that further research and target those diseases, providing the infrastructure necessary for them to succeed. These companies, in turn, rapidly advance medicines to help those who lack treatment options. Paragon has a proven track of successfully bringing new drugs to market, having received 13 FDA approvals in the last decade—which is a success record rivaled only by the biggest pharmaceutical companies.
About Paragon Biosciences
The Paragon Biosciences portfolio includes companies like Harmony Biosciences, which is dedicated to identifying, developing, obtaining regulatory approval, innovative drugs to address unmet needs for patients with sleep and central nervous system (CNS) disorders.; Castle Creek Pharmaceuticals, which develops innovative therapies for patients with rare, debilitating dermatologic conditions; and Precision BP, which is a research and development driven organization focused on developing complex treatments in rare genetic oncology diseases.
Currently, there are more than 6,000 diseases that have no cure or treatment. Paragon Biosciences is dedicated to reducing that number.
Paragon Biosciences is committed to expanding the reaches of medical possibilities. But improving lives also means being philanthropists when possible. Paragon leadership gives its support to a broad variety of organizations which work to improve the health and strength of local communities in a variety of ways. Paragon is committed to advancing the state of science and disease research, education, and community development.
About Jeff Aronin
Jeff Aronin has been involved in the healthcare and biotech industries for over two decades. He brings a wide range of experiences to his role as the CEO and founder of several pharmaceutical companies (Crunchbase). He has a solid background in advanced sciences dealing with both drug development and rare diseases. This base of experience provides him with a unique insight into the needs of the global market. He occupies a unique position because he can bring both business leaders and scientists together to design effective research methods for treatments and groundbreaking therapies. He also does community outreach and mentors prospective entrepreneurs who can benefit from the insights that only come from many years of experience in the field.
Jeff Aronin is currently serving as the CEO and chairman of Paragon Biosciences. He started working in this position in 2010, and he has led the company to be competitive on the global stage. He also serves as the non-executive chairman of other Paragon companies that are listed as portfolio holdings.
Jeff Aronin was also active in the deal with Lundbeck Inc. when it integrated the company called Ovation Pharmaceuticals. He founded Ovation Pharmaceuticals and served as the CEO of the company from its beginning in 2000 to 2009, when it was acquired by Lundbeck, Inc. The purchase of his company was finalized in 2009. He continued working for Lundbeck as its CEO during the transition process.
Jeff Aronin is driven by more than just the ambition to build great companies (https://angel.co/jeff-aronin). His ultimate goal is to improve the health outcomes of patients who might not have any other options.